We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
+38.9%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$8.13B
AUM Growth
+$1.33B
Cap. Flow
+$252M
Cap. Flow %
3.09%
Top 10 Hldgs %
38.33%
Holding
153
New
32
Increased
35
Reduced
44
Closed
13

Top Buys

Rank Stock Value
1
AGN
Allergan Inc
AGN
+$182M
2
ISRG icon
Intuitive Surgical
ISRG
+$111M
3
ESRX
Express Scripts Holding Company
ESRX
+$60.7M
4
ABBV icon
AbbVie
ABBV
+$52.2M
5
NBIX icon
Neurocrine Biosciences
NBIX
+$48.2M

Top Sells

Rank Stock Value
1
AET
Aetna Inc
AET
+$78.6M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$61.6M
3
CELG
Celgene Corp
CELG
+$61.1M
4
INCY icon
Incyte
INCY
+$58.6M
5
UNH icon
UnitedHealth
UNH
+$51.9M

Sector Composition

Rank Sector Weight
1 Healthcare 83.16%
2 Technology 0.09%
3 Financials 0.06%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VCRA
101
DELISTED
VOCERA COMMUNICATIONS, INC.
VCRA
$7.31M 0.09%
447,500
– –
VRTX icon
102
PUT
Vertex Pharmaceuticals
VRTX
$124B
$6.87M 0.08%
+97,100
New +$7.69M
FATE icon
103
Fate Therapeutics
FATE
$270M
$6.75M 0.08%
692,900
-9,100
-1% -$70.3K
ABT icon
104
Abbott
ABT
$187B
$6.7M 0.08%
174,000
-131,000
-43% -$5.05M
CBST
105
DELISTED
CUBIST PHARMACEUTICALS INC
CBST
$6.58M 0.08%
90,000
– –
BLUE
106
DELISTED
bluebird bio
BLUE
$6.57M 0.08%
+22,311
New +$6.76M
CVD
107
DELISTED
COVANCE INC.
CVD
$6.55M 0.08%
63,000
+4,000
+7% +$396K
ZTS icon
108
Zoetis
ZTS
$32.5B
$6.4M 0.08%
221,000
-58,000
-21% -$1.77M
RPTP
109
DELISTED
RAPTOR PHARMACEUTICAL CORP COM STK (DE)
RPTP
$6M 0.07%
+600,000
New +$8.66M
GWPH
110
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$5.67M 0.07%
95,500
-224,700
-70% -$13.4M
CRIS icon
111
Curis
CRIS
$9.41M
$5.5M 0.07%
975
– –
GILD icon
112
PUT
Gilead Sciences
GILD
$167B
$5.32M 0.07%
+75,000
New +$5.88M
QCOR
113
DELISTED
QUESTCOR PHARMA INC
QCOR
$5.19M 0.06%
80,000
– –
SUPN icon
114
Supernus Pharmaceuticals
SUPN
$2.77B
$5.18M 0.06%
580,000
– –
UPI
115
DELISTED
UROPLASTY INC-NEW
UPI
$4.95M 0.06%
1,363,500
-80,000
-6% -$313K
MDXG icon
116
MiMedx Group
MDXG
$649M
$4.88M 0.06%
795,400
+95,400
+14% +$701K
AET
117
DELISTED
Aetna Inc
AET
$4.72M 0.06%
63,000
-1,110,100
-95% -$78.6M
CPRX
118
DELISTED
Catalyst Pharmaceutical
CPRX
$4.28M 0.05%
1,895,000
– –
XTNT icon
119
Xtant Medical Holdings
XTNT
$59.7M
$3.99M 0.05%
39,620
+12,500
+46% +$986K
DSCI
120
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
$3.8M 0.05%
+300,000
New +$3.88M
IRWD icon
121
CALL
Ironwood Pharmaceuticals
IRWD
$626M
$3.7M 0.05%
+358,200
New +$4.03M
BSX icon
122
Boston Scientific
BSX
$68.5B
$3.67M 0.05%
+271,700
New +$3.57M
QCOR
123
CALL
DELISTED
QUESTCOR PHARMA INC
QCOR
$3.25M 0.04%
50,000
-35,000
-41% -$2.23M
ANGO icon
124
CALL
AngioDynamics
ANGO
$593M
$3.15M 0.04%
+200,000
New +$3.26M
ANTH
125
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
$3.13M 0.04%
116,594
– –
2 3 4
5
6

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

OrbiMed's Q1 2014 Portfolio in Review

As of Q1 2014, OrbiMed held 153 positions worth $8.13B, up 20% from $6.8B the previous quarter. Its ten largest holdings account for 38% of the portfolio.

OrbiMed deployed $252M of net new capital in Q1 2014, opening 32 new positions and adding to 35 existing holdings. Its largest new stake was Eli Lilly: 543,000 shares worth $32M.

By sector, the portfolio is most concentrated in Healthcare at 83% of assets, down from 84% a quarter earlier, followed by Technology and Financials.

On the sell side, the largest reduction was Aetna Inc, an estimated $78.6M trimmed.

  • OrbiMed's largest Q1 2014 buy was Eli Lilly: 543,000 shares worth $32M.
  • OrbiMed added most to Allergan Inc in Q1 2014, an estimated $182M increase.
  • OrbiMed's biggest Q1 2014 reduction was Aetna Inc, cutting an estimated $78.6M.
  • OrbiMed fully exited QIAGEN NV in Q1 2014, selling an estimated $45.9M.
  • OrbiMed's ten largest holdings make up 38% of its $8.13B portfolio in Q1 2014.
  • OrbiMed opened 32 new positions and closed 13 in Q1 2014.
  • OrbiMed's portfolio value rose 20% quarter-over-quarter to $8.13B.

Based on OrbiMed's 13F filing for Q1 2014, filed 15 May 2014.